MicroPulse Transscleral Laser Therapy safe and effective treatment for types and severities of glaucoma
MicroPulse Transscleral Laser Therapy (TLT) is a non-incisional laser treatment for glaucoma. The Cyclo G6 Laser and the MicroPulse P3 Delivery Device use an infrared diode laser at a wavelength of 810 nm in which the continuous energy wave is divided into a series of pulses, minimizing tissue temperature elevation and coagulative damage. The laser is “ON” 31.3% of the time (the duty cycle) and “OFF” 68.7% of the time. The MicroPulse technology results in a lower amount of energy being applied over time and, combined with a sweeping technique, delivers a more homogeneous distribution of energy compared to traditional transscleral cyclophotocoagulation (CPC) technique. Lower temperature targets and greater thermal control with MicroPulse TLT contribute to lower the risk of complications compared to continuous wave transscleral cyclophotocoagulation. Furthermore, the recently modified delivery probe has an improved ergonomic design that allows for more stable positioning during the treatment. It also facilitates a more posterior application of laser energy, farther away from the anterior segment structures such as the lens and the iris root
In an effort to refine treatment technique, patient selection, and outcomes of MicroPulse TLT, an international panel of ten glaucoma specialists was formed. The panel published its first paper, “Evidence-based consensus guidelines series for MicroPulse Transscleral Laser Therapy - Dosimetry & Patient Selection”, providing the rationale and recommendations for standard starting dose MicroPulse TLT settings using the revised MicroPulse P3 probe. The publication by Grippo et al summarized the current conceptual understanding of MicroPulse TLT including mechanism of action, indications, cautions in patient selection, and dosimetry. The recommended starting settings for MicroPulse TLT are 2500 mW, 31.3% duty cycle, and 4 sweeps at a sweep velocity of 20 seconds per hemisphere for a total of 160 seconds per eye. This publication also provided guidance on dose escalation of treatment. This same international panel met again to establish consensus on treatment technique, post-procedural management, expected outcomes, and retreatments or enhancements.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.